A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701)
{{output}}
Background: Based on the reported antitumor effects of microtubule inhibitors in xenograft models of BRAF V600E mutant colorectal cancer, this multicenter phase II study aimed to evaluate the efficacy and safety of eribulin in pa... ...
